文献速递肿瘤 PET/CT核素与放射性配体治疗

90Y玻璃微球放射栓塞治疗肝细胞癌:治疗前11C-乙酸盐与18F-FDG PET/CT及治疗后90Y PET/CT在个体化剂量处方中的意义

Radioembolization with 90Y glass microspheres for hepatocellular carcinoma: significance of pretreatment 11C-acetate and 18F-FDG PET/CT and posttreatment 90Y PET/CT in individualized dose prescription.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-06-11

本研究前瞻性纳入62例肝细胞癌患者,以治疗前双示踪剂11C-乙酸盐和18F-FDG PET/CT作为肿瘤细胞分化替代标志物,验证治疗后90Y PET/CT剂量学,并评估不同示踪剂组肿瘤剂量与疗效的关系。结果显示90Y PET/CT测量准确,治疗前99mTc-MAA SPECT/CT肿瘤/非肿瘤比值可预测治疗后90Y PET/CT比值,良好缓解的肿瘤剂量阈值随细胞分化程度不同而异。

要点

  • 90Y PET/CT测量注入90Y活度回收率为81.9-99.9%,中位数94.8%。
  • 治疗前SPECT/CT T/NTMAA与治疗后90Y PET/CT T/NT90Y强相关(r=0.918,P<0.05)。
  • 良好缓解的肿瘤剂量阈值:低分化262 Gy,高/中分化152/174 Gy。

核心结论

  • 90Y PET/CT可为90Y-GMRE提供准确剂量学。
  • 治疗前T/NTMAA可预测治疗后T/NT90Y。
  • 良好缓解的肿瘤剂量阈值取决于示踪剂类型,肝细胞癌放射敏感性与细胞分化及其他PET参数强相关。
  • 这些细胞动力学因素可提高疗效同时减少器官损伤,用于个体化90Y-GMRE处方。

研究设计与样本

  • 前瞻性纳入62例接受90Y-GMRE的肝细胞癌患者。
  • 治疗前行双示踪剂11C-乙酸盐和18F-FDG PET/CT作为肝细胞癌细胞分化的替代标志物。
  • 治疗前99mTc-MAA SPECT/CT肿瘤/非肿瘤比值(T/NTMAA)经量化验证后与治疗后90Y PET/CT T/NT90Y进行相关性分析。
  • 治疗后2个月随访PET/CT评估不同示踪剂组肝细胞癌的肿瘤剂量-疗效关系。

主要发现

  • 90Y PET/CT测量注入90Y活度回收率为81.9-99.9%,中位数94.8%。
  • 治疗前SPECT/CT T/NTMAA与治疗后90Y PET/CT T/NT90Y强相关(5.6±3.2 vs 5.9±3.5,T/NT90Y=1.01×T/NTMAA+0.161,r=0.918,P<0.05)。
  • 高分化、中分化和低分化肝细胞癌的缓解率分别为72.4%(21/29)、70.6%(12/17)和25%(4/16)。
  • 低分化与高/中分化肝细胞癌良好缓解的肿瘤剂量截断值显著不同(262 Gy vs 152/174 Gy),敏感度89.2%,特异度88%。
  • 在肝脏限耐受剂量70 Gy时,预测良好缓解的T/NTMAA阈值在低分化为3.5,在高/中分化为2.0/2.3。

关键数值与推荐

  • 良好缓解的肿瘤剂量截断值:低分化肝细胞癌262 Gy,高/中分化肝细胞癌152/174 Gy,敏感度89.2%,特异度88%。
  • 肝脏限耐受剂量70 Gy时,预测良好缓解的T/NTMAA阈值:低分化3.5,高分化2.0,中分化2.3。
  • 不考虑细胞分化时,良好缓解的肿瘤剂量截断值为170 Gy,敏感度70.3%,特异度76%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to establish an algorithm for the prescription of 90Y glass microsphere radioembolization (90Y-GMRE) of HCC in individual patients based on the relationship between tumour dose (TD) and response validated by 90Y PET/CT dosimetry and dual-tracer PET/CT metabolic parameters. METHODS: The study group comprised 62 HCC patients prospectively recruited for 90Y-GMRE who underwent pretreatment dual-tracer (11C-acetate and 18F-FDG) PET/CT as surrogate markers of HCC cellular differentiation. Pretreatment tumour-to-nontumour ratio on 99mTc-MAA SPECT/CT (T/NTMAA) was correlated with posttreatment 90Y PET/CT T/NT90Y after quantification validation. The TD-response relationship for HCC of different tracer groups was assessed on follow-up PET/CT 2 months after treatment. RESULTS: 90Y PET/CT was accurate in the measurement of recovery of injected 90Y activity (81.9-99.9%, median 94.8%). Pretreatment SPECT/CT T/NTMAA was strongly correlated with posttreatment 90Y PET/CT T/NT90Y (5.6 ± 3.2 versus 5.9 ± 3.5, T/NT90Y 1.01 × T/NTMAA + 0.161, r = 0.918, P < 0.05). The response rates were 72.4% (21/29), 70.6% (12/17) and 25% (4/16) for well, moderately and poorly differentiated HCC, respectively. The cut-off TD for a good response was significantly different between poorly differentiated and well/moderately differentiated HCC (262 Gy versus 152/174 Gy) with 89.2% sensitivity and 88% specificity. At a limiting tolerated liver dose of 70 Gy, the T/NTMAA thresholds for predicting a good response in poorly differentiated and well/moderately differentiated HCC were 3.5 and 2.0/2.3. Disregarding HCC cellular differentiation, the cut-off TD became 170 Gy, with lower sensitivity (70.3%) and specificity (76%). CONCLUSION: 90Y PET/CT can provide accurate dosimetry for 90Y-GMRE. Pretreatment T/NTMAA predicts posttreatment T/NT90Y. The TD thresholds for a good response are tracer-dependent, with a strong correlation between HCC radiosensitivity and cellular differentiation and other PET-based parameters. These cytokinetic factors improve treatment efficacy while minimizing organ damage for the prescription of personalized 90Y-GMRE.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Ho CL, Chen S, Cheung SK, et al. Radioembolization with 90Y glass microspheres for hepatocellular carcinoma: significance of pretreatment 11C-acetate and 18F-FDG PET/CT and posttreatment 90Y PET/CT in individualized dose prescription. Eur J Nucl Med Mol Imaging. 2018. PMID: 29948107. doi:10.1007/s00259-018-4064-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。